{
    "id": 20532,
    "cites": 52,
    "cited_by": 6,
    "reference": [
        "Acemoglu, D. and Linn, J., 2004. Market size in innovation: Theory and evidence from the pharmaceutical industry. The Quarterly Journal of Economics 119 (3), 1049-1090.",
        "Aitken, M., Berndt, E., Cutler, D., 2009. Prescription drug spending trends in the U.S.: Looking beyond the turning point. Health Affairs 28(1), 151-160.",
        "Arcidiacono, P., Ellickson, P. B., Landry, P., Ridley, D. B., 2013. Pharmaceutical followers. International Journal of Industrial Organization 31(5), 538-553.",
        "Berndt, E., Mortimer, R., Bhattacharjya, A., Parece, A., Tuttle, E., 2007. Authorized generic drugs, price competition and consumers\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 welfare. Health Affairs 26(3), 790-799.",
        "Berndt, E., Aitken, M., 2010. Brand loyalty, generic entry, and price competition in pharmaceuticals in the quarter century after the 1984 Hatch-Waxman legislation. NBER Working Paper No. 16431.",
        "Bokhari, F. A., Fournier, G. M. 2013. Entry in the ADHD drugs market: Welfare impact of generics and me\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u0090too&apos;s. The Journal of Industrial Economics 61(2), 339-392.",
        "Branstetter, L., Chatterjee, C., Higgins, M. 2013. Regulation and welfare: Evidence from Paragraph IV generic entry in the pharmaceutical industry. Revision of NBER working paper 17188.",
        "Budish, E., Roin, B., Williams, H. 2013. Do fixed patent terms distort innovation? Evidence from cancer clinical trials. NBER Working Paper 19340.",
        "Caves, R., Whinston, M., Hurwitz, M., 1991. Patent expiration, entry and competition in the U.S. pharmaceutical industry. Brookings Papers on Economic Activity: Microeconomics, 1-48.",
        "Ceccagnoli, M., Graham, J., S., Higgins, J., M., Lee, J. 2010. Productivity and the role of complementary assets in firms\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 demand for technology innovations. Industrial and Corporate Change, 19(3), 839-869.",
        "Chan, T., Nickerson, A., J, Owan, H. 2007. Strategic management of R&D pipelines with cospecialized investments and technology markets. Management Science 53, 667\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c682.",
        "Chiou, J., Magazzini, L., Pammoli, F., Riccaboni, M., 2012.The value of failure in pharmaceutical R&D. Unpublished working paper, IMT Lucca EIC Working Paper Series 01.",
        "Cleanthous, P., 2002. Patient welfare implications of innovation in the U.S. antidepressant market. Unpublished working paper, New York University.",
        "Cockburn, I. M. 2006. Is the pharmaceutical industry in a productivity crisis? in Innovation Policy and the Economy, Jaffe, A. B., Lerner, J. & Stern, S. (eds), 7(1), 1\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c32, The MIT Press.",
        "Cohen, W., 2010. Fifty Years of Empirical Studies of Innovative Activity and Performance. In Brownyn H. Hall and Nathan Rosenberg (ed.), Handbook in Economics of Innovation, North-Holland.",
        "Cohen, W., Nelson, R., Walsh, J., 2002. Links and impacts: The influence of public research on industrial R&D. Management Science 48(1), 1 \u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c 23.",
        "Congressional Budget Office, 1998. How increased competition from generic drugs has affected process and returns in the pharmaceutical industry. Congressional Budget Office, The Congress of the United Sates, http://www.cbo.gov.",
        "DiMasi, J., Hansen, R., Grabowski, H., 1991. Cost of innovation in the pharmaceutical industry. Journal of Health Economics 10(2), 151-185.",
        "DiMasi, J., Hansen, R., Grabowski, H., 2003. The price of innovation: new estimation of drug development costs. Journal of Health Economics 22, 151-185.",
        "DiMasi, J. A., Grabowski, H. G., 2012. R&D costs and returns to new drug development: a review of the evidence. Tufts Center for the Study of Drug Development. March/April CSDD Impact Report. The Oxford handbook of the economics of the biopharmaceutical industry. Oxford University Press, Oxford, 21-46.",
        "Dunn, A. 2012. Drug innovations and welfare measures computed from market demand: The case of anticholesterol drugs. American Economic Journal: Applied Economics 4(3), 167-189.",
        "Ellickson, P., Stern, S., Trajtenberg, M. 2001. Patient welfare and patient compliance-An empirical framework for measuring the benefits from pharmaceutical innovation. In Medical Care Output and Productivity (pp. 539-564). University of Chicago Press.",
        "Federal Trade Commission, 2002. Generic entry prior to patent expiration: FTC study. U.S. Government Printing Office, Washington, D.C., July.",
        "Fuchs, Victor, 1982. Who Shall Live? Health, Economics, and Social Choice. Wiley, New York.",
        "Furman, J.L., Kyle, K., M. Cockburn, I. Henderson, M., R. 2006. Public and private spillovers, location, and the productivity of pharmaceutical research. NBER Working Paper Number 12509.",
        "General Accounting Office, 2012. Research on Savings from Generic Drug Use. GAO-12371R. http://www.gao.gov/assets/590/588064.pdf Gittelman, M., Kogut, B., 2003. Does good science lead to valuable knowledge? Biotechnology firms and the evolutionary logic of citation patterns. Management Science 49 (4), 366\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c382.",
        "Golec, J., Hegde, S., Vernon., M. J., 2010.Pharmaceutical R&D spending and threats of price regulation. Journal of Financial and Quantitative Analysis 45, 239-264.",
        "Grabowski, H., 2007. Competition between generic and branded drugs. In Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective, Sloan, F., Hsieh, C. (eds.), Cambridge University Press: Cambridge, MA.",
        "Grabowski, H., Kyle, M., 2007. Generic competition and market exclusivity periods in pharmaceuticals. Managerial and Decision Economics 28, 491-502.",
        "Hausman, J., Hall, H. B., Griliches, Z. 1984. Econometric models for count data with an application to the patents-R&D relationship. Econometrica 52, 909-938.",
        "Hausman, J., Lo, A., MacKinlay, C. 1992. An ordered probit analysis of transaction stock prices. Journal of Financial Economics 34, 83-104.",
        "Hemphill, S., Sampat, B., 2011. When do generics challenge drug patents. Journal of Empirical Legal Studies 8(4), 619-649.",
        "Hemphill, C., Sampat, B., 2012. Evergreening, patent challenges, and effective market life in pharmaceuticals. Journal of Health Economics, 327-341.",
        "Higgins, M.J., Graham, S., 2009. Balancing innovation and access: patent challenges tip the scales. Science 326, 370-372.",
        "Higgins, M.J., Thursby, J., Thursby, M., 2014. Bench-to-bench bottlenecks in translation. Science Translational Medicine 6, 250fs32.",
        "Hughes, J., Moore, M., Snyder, E., 2002. Napsterizing pharmaceuticals: Access, innovation and consumer welfare. NBER Working Paper No. 9229.",
        "Knowles, S., 2010. Fixing the legal framework for pharmaceutical research. Science 327, 1083-1084.",
        "Lichtenberg, F. R. 2001. The benefits and costs of newer drugs: Evidence from the 1996 medical expenditure panel survey. NBER Working paper 8147.",
        "Lichtenberg, F. R. 2004. Public policy and innovation in the U.S. pharmaceutical industry. In: HoltzEakin, D., Rosen, H. (eds), Entrepreneurship and Public Policy. MIT Press, Cambridge, MA.",
        "Lichtenberg, F. R. 2007. The impact of new drug launches on U.S. longevity and medical expenditure. American Economic Review 97, 438-441.",
        "Mansfield, E. 1995. Academic research underlying industrial innovation: Sources, characteristics and financing. Review of Economics and Statistics 77, 55-65.",
        "Mossinghoff, G., 1999. Overview of Hatch-Waxman act and its impact on the drug development process. Food and Drug Law Journal 54(2), 187-194.",
        "New York Times, 1989. The Generic Drug Scandal. October 2, 1989.",
        "Nordhaus, D., William. 1999. The health of nations: The contribution of improved health to living standards. NBER working paper 8818, accessed at http://nordhaus.econ.yale.edu/health_nber_w8818.pdf Pammolli, F., Magazzini, L., Riccaboni, M., 2011.The productivity crisis in pharmaceutical R&D. Nature Reviews Drug Discovery 10, 428-438.",
        "Panattoni, L., 2011. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms. Journal of Health Economics 30, 126-145.",
        "Reiffen, D., Ward, M., 2005. Generic drug industry dynamics. Review of Economics and Statistics 87, 37-49.",
        "Roin, B., 2014. Solving the problem of new uses. Michigan State Law Review, forthcoming. http://ssrn.com/abstract=2337821.",
        "Saha, A., Grabowski, H., Birnbaum, H., Greenberg, P., Bizen, O., 2006. Generic competition in the US pharmaceutical industry. International Journal of the Economics of Business 13, 15-38 Scherer, F. M., 2010. Pharmaceutical Innovation. In Brownyn H. Hall and Nathan Rosenberg (ed.), Handbook in Economics of Innovation, North-Holland.",
        "Teece, D.J. 1986. Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy, Research Policy 15, 286-305.",
        "Trusheim, M., Aitken, M., Berndt, E., 2010. Characterizing markets for biopharmaceutical innovations: Do biologics differ from small molecules? Forum for Health Economics and Policy 13(1), 1-43.",
        "Wong, G., 2009. Biotech scientists bank on big pharma\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s biologics push. Nature Biotechnology 27, 293295.",
        "Wooldridge, J., 1999. Distribution-free estimation of some nonlinear panel data models. Journal of Econometrics 90(1), 77-97."
    ]
}